Clinical Diagnostics

Clinical Diagnostics from Metabolomics

Metabolon’s clinical team has created metabolomics-driven tests that give healthcare providers actionable information to aid in patient management. 

We currently have three laboratory-developed tests (LDTs) that are run in our Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited facility:

  • QUANTOSE® IR is Metabolon’s first commercially available laboratory test for obesity-related chronic diseases. It assesses the level of insulin resistance and provides treatment monitoring for prediabetes. Clinical intervention at this stage of disease could help delay or prevent the onset of type 2 diabetes. Quantose IR is currently available in the U.S., Mexico and Europe.
  • QUANTOSE® IGT reflects the degree of impaired glucose tolerance in an individual. Impaired glucose tolerance (IGT) is a known risk factor for prediabetes. Our test is designed to easily differentiate IGT from normal glucose tolerance with only a single, fasted blood draw.
  • META IMD™ screens for more than 65 inherited metabolic disorders using a single biological sample. To learn more, click here.

Diagnostics Pipeline
Looking forward, Metabolon is focused on developing and delivering additional clinical diagnostics and prognostic tools for obesity-related chronic diseases and potentially many other clinical areas. We are currently developing tests for:

  • Liver disease (NASH)
  • Kidney function (GFR) | accuGFR™
  • Global Health Assessment

We believe that our pipeline of precision medicine diagnostics could become important tools for the early detection of diseases and provide information that may help health care providers better manage their patients' care.

Click here to learn more about our Product Pipeline.

All of our clinical diagnostics and pipeline products have been developed using Metabolon’s proprietary metabolomics technology. Our global metabolomics screening technology enables the rapid discovery of clinically relevant metabolite biomarkers and their efficient translation into clinical practice. This technology holds the potential to accelerate the discovery and development of novel clinical diagnostics that may advance the management of some major human diseases.

Click here to learn more about our technology.